Boehringer Ingelheim's Jeff Huth Elected as National Pharmaceutical Council's Chairman of the Board

Boehringer Ingelheim's Jeff Huth Elected as National Pharmaceutical Council's
                            Chairman of the Board

PR Newswire

WASHINGTON, Nov. 8, 2013

WASHINGTON, Nov. 8, 2013 /PRNewswire-USNewswire/ -- The National
Pharmaceutical Council (NPC) today announced that Jeff Huth, Senior Vice
President, Managed Markets, Boehringer Ingelheim Pharmaceuticals Inc. (BI),
has been elected chairman of its Board of Directors for 2013-14. Mr. Huth has
served on NPC's Board since 2009 and has previously held the positions of vice
chair and treasurer.

(Photo: http://photos.prnewswire.com/prnh/20131108/DC13524)

"Throughout his tenure on our board, Jeff has been dedicated to promoting NPC
and its role as a leading health care policy research organization," said NPC
President Dan Leonard. "We're looking forward to having Jeff play an even more
active role in leading NPC's efforts on issues related to balancing the needs
of patients with the population, the value of pharmaceuticals, and the use of
real-world evidence."

Mr. Huth has more than 30 years of experience in the pharmaceutical industry,
where he has served in a wide spectrum of roles ranging from pre-clinical
development to marketing and sales management. His career with Boehringer
Ingelheim has included international assignments at BI's affiliate in the
United Kingdom and at corporate headquarters in Germany. Upon returning to the
U.S., he assumed responsibility for marketing and in 2009 moved to his current
position, for which he is responsible for pricing and contracting, trade
relations, health economics and leading field-based teams interacting with
customers in the private and government payer channels. In the U.S., BI
develops and markets therapies in the respiratory, cardiovascular, metabolic,
anti-viral and oncology areas.

The NPC Board also elected Anne Whitaker, President, North America
Pharmaceuticals, Sanofi, as Vice Chair; David Martin, Vice President, Managed
Markets, Value & Access Group, Eisai Inc. as Treasurer; and Giovanni Caforio,
MD, President, U.S. Pharmaceuticals, Bristol-Myers Squibb Company, and Steven
Romano, MD, Senior Vice President, Head, Medicines Development Group, Pfizer
Inc, to serve on the executive committee.

About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization
dedicated to the advancement of good evidence and science, and to fostering an
environment in the United States that supports medical innovation. Founded in
1953 and supported by the nation's major research-based pharmaceutical
companies, NPC focuses on research development, information dissemination, and
education on the critical issues of evidence, innovation and the value of
medicines for patients. For more information, visit www.npcnow.org and follow
NPC on Twitter @npcnow.

SOURCE National Pharmaceutical Council

Website: http://www.npcnow.org
 
Press spacebar to pause and continue. Press esc to stop.